ORFonyx

Most genetic medicines aim to silence faulty genes, but some diseases result from genes that are underactive, not overactive.

Orfonyx is developing a new class of therapies that enhance gene expression by acting on precise regions of RNA, the molecules that transfer genetic instructions from DNA. By upregulating specific proteins, including those patients currently lack, the company is opening new possibilities for previously untreatable diseases.